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 ABSTRACT                                                                                                                                            
Severe congenital neutropenia (Kostmann Syndrome)
Soad Khalil Al-Jaouni.
Department of Hematology, Faculty of Medicine, King Abdulaziz University, 
Jeddah, Kingdom of Saudi Arabia
Severe congenital neutropenia (SCN), Kostmann syndrome is a heterogenous disorder 
of myelopoiesis characterized by severe chronic neutropenia, absolute neutrophil count 
(ANC) persistently below 0.50 x 109/L, with maturation arrest of neutrophil precursors 
in the bone marrow; and associated with serious recurrent bacterial infections from early 
infancy. Sepsis mortality is reduced by an advent of granulocyte colony stimulating 
factor (G-CSF) therapy.
More than 90% of patients respond to G-CSF therapy. However, hematopoietic stem cell 
transplantation has shown promise in the treatment of non-responders. About 60-80% of 
SCN cases are associated with constitutive mutations in one copy of the gene encoding 
neutrophil elastase ELA2. Myelodysplastic syndrome and acute myeloid leukemia 
(MDS/AML) have been reported. The hazard of MDS/AML increases significantly 
overtime. Approximately 10% of patients with severe congenital neutropenia develop 
AML. This is not thought to be the direct result of G-CSF therapy but related to the 
underlying disease itself.
Corresponding Author:
Soad Khalil Al-Jaouni, 
E-mail: saljaouni@kau.edu.sa
Key Words:
Myeloid leukemia, congenital neutro-
penia, kostmann’s syndrome, myelo-
dysplastic syndrome.
INTRODUCTION                                                                     
Neutrophils play a vital role in protect-
ing the body against invasion by bac-
teria. Severe chronic neutropenia is a 
general term for conditions with abso-
lute neutrophil count (ANC) of less than 
0.50x 109/L, lasting for months or years. 
Chronic neutropenia is caused by a va-
riety of hematological, immunological, 
metabolic and infectious diseases1.
The category of SCN was first clearly 
described by Kostmann in 1956 in Swed-
ish kindred. An alternative name for 
Kostmann syndrome is infantile genetic 
agranulocytosis2. Kostmann syndrome 
represents an autosomal recessive, het-
erogenous hematological disorders, 
characterized by extremely low circu-
lating neutrophils and maturation ar-
2
 (Kostmann Syndrome)
rest at the promyelocyte-myelocyte in 
the bone marrow. Neutrophil counts in 
these patients are typically <0.2x 109/L, 
with the majority presenting with life-
threatening infection during the first 6 
months of life. SCN with similar clini-
cal features occurs as an autosomal 
dominant disorder and many sporadic 
cases also have been reported3.
Other conditions grouped with se-
vere congenital neutropenia (CN) in-
clude Shwachman-Diamond syndrome 
(SDS); inborn errors of metabolism 
(e.g., glycogen-storage disease, type 
Ib)4; severe combined immunodefi-
ciency (SCID) syndromes; hyper-IgM 
syndrome and a few other conditions3,32 
Patients with clinically mild disease, 
generally tend to have a less abnormal 
bone marrow.  The estimated frequency 
of these conditions is approximately 
1-2 cases per million population.
Pathophysiology:
Neutropenia refers to an ANC that is 
two or more standard deviations below 
the age related mean. Normal neutro-
phil levels differ according to age and 
race. In general, an ANC is calculated 
by multiplying the total leukocyte count 
per milliliter by the percentage of neu-
trophils and immature neutrophil form. 
In general, an ANC of 1000–1500/mm3 
indicates mild neutropenia; 500-1000/
mm3 indicates moderate neutropenia; 
and less than 500/mm3 indicates severe 
neutropenia. This classification is use-
ful for predicting risk of infections.
Mortality/Morbidity:
The mortality rate is 70% within the 
first year of life in the absence of medi-
cal intervention with G-CSF and/or he-
matopoietic stem cell transplantation.
The classic Kostmann syndrome is rec-
ognized in early infancy with an equal 
incidence in males and females. Severe 
neutropenia is brought to clinical at-
tention after an initial infection which 
typically occurs shortly after birth. 
Symptoms of Kostmann include the 
followings: Temperature instability in 
newborn period, fever, irritability and 
localized sites of infection.
Physical and signs of Kostmann syn-
drome include the followings: Oral 
ulcers, gingivitis, pharyngitis, sinusitis 
and/or otitis media, bronchitis and/or 
pneumonia, cellulitis, cutaneous ab-
scess and/or boils, perianal abscess, 
lung or liver abscess, enteritis with 
chronic diarrhea and vomiting. Bac-
teremia and/or septicemia occur, most 
commonly from streptococci or staphy-
lococci; other organisms include Pseu-
domonas, fungi and in rare cases Clos-
tridium species. 
Pathogenesis of congenital neutrope-
nia:
The underlying genetic defect of SCN 
is still only partially understood. Some 
investigators have proposed that Kost-
mann syndrome represents a defect in 
the regulation or production of granu-
locyte colony-stimulating factor (G-
CSF).
An abnormal G-CSF-induced intracel-
lular signal transduction pathway has 
been suggested as a potential cause of 
the underlying genetic defect. Neutro-
phils from patients are shown to have 
dramatically increased levels of 2 cyto-
solic protein tyrosine phosphatases that 
contain Src-homology 2 domain (SH2 
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domain): Anti-Src Homology Phos-
phatase-1 (SHP-1) and Src Homology 
Phosphatase 2 (SHP2). One hypothesis 
is that over expression of these proteins, 
which are involved in cytokine receptor 
signaling, plays a role in altering intra-
cellular signal transduction processes.
A selective decrease of B-Cell Lym-
phoma-2 (BCL-2) expression in my-
eloid cells and an increase in apoptosis 
in bone marrow progenitor cells have 
been observed. The primary function 
of BCL-2, a mitochondria-targeted pro-
tein, is the prevention of Cytochrome 
release. Cytochrome has the capability 
of activating a cytosolic caspases cas-
cade. Caspases are integral proteolytic 
enzymes involved in cellular apoptosis. 
They are activated through one of two 
pathways: 
1. An extrinsic, death receptor-depen-
dent pathway or.
2. An intrinsic, mitochondria-depen-
dent pathway. Mitochondrial re-
lease of Cytochrome c serves to 
initiate the cytosolic caspases cas-
cade through the second pathway. 
The decreased BCL-2 results in an 
enhanced release of Cytochrome 
c, which then perpetuates the cas-
pases cascade leading to more pro-
nounced apoptosis. 
In Kostmann syndrome, the G-CSF re-
ceptors are expressed on myeloid cells 
in slightly increased numbers and the 
binding affinity for G-CSF to its recep-
tors is normal. This is in contrary to 
the original theory that the underlying 
Kostmann defect was related to either 
decreased G-CSF production or dimin-
ished binding of G-CSF to its receptor.5
The Severe Chronic Neutropenia Inter-
national Registry (SCNIR) is an impor-
tant resource for studies on genetic and 
molecular bases for disorders causing 
severe chronic neutropenia.
Approximately 60-80% of SCN cases 
are associated with inherited or spon-
taneous point mutation in one copy 
of the gene encoding neutrophil elas-
tase ELA2. This mutation is found in 
the analysis of congenital neutropenia 
(CN) families with autosomal dominant 
inheritance. 
Although neutrophil elastase mutations 
have been found in a subgroup of pa-
tients with Kostmann syndrome, as in 
cyclic neutropenia. Adverse events in-
clude the development of acute myeloid 
leukemia in approximately 7% of the 
patients within the cohort of patients 
with Kostmann’s syndrome suggesting 
that congenital neutropenia is a preleu-
kemia syndrome. None of the patients 
with cyclic of idiopathic neutropenia 
developed leukemia.1, 6
A subset of SCN patients harbor ac-
quired somatic mutations in the CSF3R 
gene; encoding the granulocyte colony-
stimulating factor receptor (G-CSF-R), 
which has shown a strong predisposi-
tion to acute myeloid leukemia7, 8.These 
mutations truncate the intracellular 
domain, producing strong hyper-prolif-
eration, but with defective maturation 
due to defective internalization and loss 
binding sites for several negative regu-
lators, thus lead to extended signaling 
especially of STAT5 (Signal transduc-
er and activator of transcription 5)9-12. 
Other studies reported a further subset 
of SCN patients, with constitutive mu-
tations in the extracellular domain of 
the G-CSF-R that collectively act in a 
dominant-negative manner leading to 
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hypo-responsiveness to G-CSF.13, 14
Studies of the G CSF gene have shown 
that mutation occur mainly within a 
critical region of the intracellular part 
of the receptor.16, 18
Using a positional cloning approach and 
candidate gene evaluation in autosomal 
recessive severe congenital neutropenic 
patients (Kostmann disease) were iden-
tified a recurrent homozygous germ line 
mutation in HAX1. HAX1 encodes the 
mitochondrial protein HAX1, which 
has been assigned functions in signal 
transduction and cytoskeletal control. 
HAX1 is a critical for maintaining the 
inner mitochondrial membrane poten-
tial and protecting against apoptosis 
in neutrophil development, HAXI de-
ficiency causes autosomal recessive 
Kostmann disease.15, 33
Diagnosis:
Severe Congenital Neutropenia is usu-
ally detected in infancy after fever or 
signs of severe infection develop. Pa-
tients have ANCs continuously below 
0.2 x 109/L; in many cases, periph-
eral blood neutrophils are completely 
absent. With infection, there may be a 
transient increase in neutrophils, but 
counts rarely increase to normal levels. 
Repeated differential blood counts in-
dicate persistent ANCs within a range 
of 0 to 0.2 x 109/L is required for di-
agnosis. Blood counts often indicate 
mild anemia and thrombocytosis. There 
is usually a two to four fold increase in 
blood monocytes and an increase in the 
blood eosinophils count is common. 
IgG levels are elevated in the majority 
of patients. The specific immunologic 
competence after vaccination is normal. 
Blood chemistry is within the normal, 
age dependent range for electrolytes, 
kidney and liver functions. Testing for 
anti-neutrophil antibodies is helpful to 
exclude autoimmune neutropenia of in-
fancy.
The bone marrow usually shows matu-
ration arrest of neutrophil precursors at 
an early stage (Promyelocyte/myelo-
cyte level) with few cells of the neu-
trophilic series. Promyelocytes often 
have morphologically atypical nuclei 
and vacuolization of cytoplasm. The 
absolute number of promyelocytes is 
slightly increased. Megakaryocytes 
are normal in number and morphology. 
In vitro growth of granulocyte macro-
phage progenitor cell is defective, with 
few colonies formed and evidence for 
“Maturation arrest”. Cytogenetic at the 
time of diagnosis of CN are almost al-
ways normal. Bone marrow cytogenet-
ics may change during the course of the 
disease, with monosomy 7 being the 
most frequent aberration in about 50% 
of abnormal cytogenetic results. The in-
terval from the original finding of nor-
mal cytogenetics to the appearance of 
an abnormality is often several years. 
Abnormal cytogenetics is often associ-
ated with morphologic changes of the 
bone marrow indicating the develop-
ment of MDS or Leukemia. 
Differential Diagnosis:
The differential diagnosis of CN in-
cludes a number of congenital and ac-
quired diseases17. The most common 
difficulty is determining whether the 
patient has cyclic neutropenia, autoim-
mune neutropenia of infancy, or idio-
pathic neutropenia. Cyclic neutropenia 
is diagnosed by serial measurement of 
blood neutrophils on at least 3 days per 
week for at least 6 weeks, graphing the 
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count. Cyclic neutropenia is also a he-
reditable disease. Family and genetic 
studies show that it is an autosomal 
dominant disorder19. An important dif-
ferential diagnostic evaluation is testing 
for neutrophilic antibodies20. Although 
these infants lack peripheral blood neu-
trophils, the marrow function is nor-
mal; maturation of myeloid precursors 
to mature neutrophil stage is usually 
observed. Neutrophil or granulocyte 
specific antibodies in serum are detect-
able using immunologic test. Idiopathic 
neutropenia is a form of acquired neu-
tropenia, it includes patients without 
evidence of congenital, neoplastic, or 
immunological causes of neutropenia, 
the clinical phenotype is similar to au-
toimmune neutropenia. Patients are cat-
egorized as having idiopathic neutro-
penia unless they are positive for anti 
neutrophil antibodies.21, 22
Therapy:
Severe CN is often recognized when 
patients present with life-threatening 
infection during the few months of 
life and are found to have extremely 
low circulating neutrophils. Antibiotic 
therapy for these infections follows the 
same principles as for other patients: 
broad-spectrum antibiotics for severe 
infections until the pathogen is identi-
fied; targeted therapy for specific patho-
gens; administration of antibiotics until 
the signs and symptoms of infection 
have cleared. Prophylactic antibiotics 
may be considered, but are required in-
frequently since the advent of G-CSF in 
198723. Recombinant human granulo-
cyte colony-stimulating factor (rHuG-
CSF) requires long-term daily adminis-
tration to maintain clinical benefit. The 
ANC should not be the sole indicator 
of clinical efficacy. Individual adjust-
ment of dosages on the basis of both the 
patient’s clinical course and the ANC. 
The efficiency of rHuG-CSF has been 
demonstrated by increasing the number 
of neutrophils with reduction of infec-
tion23, 24. In contrast, GM-CSF treatment 
did not led to an increase in blood neu-
trophils, but only in blood eosinophils25. 
In 1994, the SCNIR collected data from 
more than 600 patients with CN, results 
demonstrated that more than 95% re-
sponded to rHuG-CSF treatment with 
an increase in ANCs to 1.0 x ≥109/L.3 
Most CN patients responded to a dose 
between 3 and 10 mg/kg/d.16,17
Generally, rHuG-CSF should be initi-
ated at 5 mg/kg/day, the dose should 
be escalated to 10 mg/kg/day and then 
by increments of 10 mg/kg/day at 14-
days intervals if the ANC remains be-
low 1.0 x 109/L. As soon as the ANC 
can be maintained at 1.0 to 1.5 x 109/L 
or above, further increase in rHuG-CSF 
dose can be stopped since the occur-
rence of bacterial infection is reduced 
dramatically at this level. The dose of 
rHuG-CSF can be reduced if the ANC 
increases to ≥5.0 x 109/L to keep the 
patient at the lowest dose necessary for 
maintaining sufficient neutrophil count 
to overcome infections.23, 29
Non responders to rHuG-CSF are de-
fined by failure to benefit at dose lev-
els exceeding 120 mg/kg/day. Partial 
responders have ANCs increased to 0.5 
to 1.0 x 109/L but still have bacterial in-
fections. In some patients, the dose of 
rHuG-CSF cannot be increased to these 
levels because of the large volume and 
frequency of injections required. Pa-
tient was refractory to standard and 
high dose G-CSF therapy, but respond-
ed to a combined corticosteroid/G-CSF 
treatment, apparently through synergis-
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tic activation of STAT5 and stimulate 
G-CSF-induced cell proliferation.26, 27
All responding patients require signifi-
cantly fewer antibiotics and fewer days 
of hospitalization.  Hematopoietic stem 
cell transplantation (HSCT) remains the 
only currently available treatment for 
patients who are refractory to rHuG-
CSF treatment or in those with leuke-
mic transformation.28
Adverse events to rHuG-CSF therapy 
include mild splenomegaly, osteoporo-
sis and malignant transformation into 
MDS/Leukemia. If and how G-CSF 
treatment impacts on these adverse 
events is not fully understood. The haz-
ard of MDS/Leukemia increases signif-
icantly overtime.
In the study of Rosenberg, et al.29, the 
hazard of MDS/AML increased sig-
nificantly during the period of obser-
vation of SCN on G-CSF, from 2.9% 
per year after 6 years to 8.0% per year 
after 12 years. The cumulative inci-
dence of MDS/AML was 21% after 10 
years. The risk of MDS/AML increased 
with the dose of G-CSF. Less respon-
sive patients, defined as those requiring 
greater than 8 mg/kg/d of G-CSF, had 
a cumulative incidence of MDS/AML 
of 40% after 10 years and compared to 
11% of more responsive patients. The 
data were interpreted as indicating that 
a poor response to G-CSF defines an 
“at-risk” population and predicts an ad-
verse outcome.29
Conversion to MDS/AML in CN pa-
tients was associated with one or more 
cellular genetic abnormalities (Such as 
monosomy7 and as mutation or G-CSF-
R mutation), which may be useful for 
identifying subgroups of patients at high 
risk. Marrow cells from approximately 
75% of the severe CN cases that trans-
formed to MDS/AML also show point 
mutations in the gene for the G-CSF-
R; resulting in a truncated C-terminal 
cytoplasmic region of the receptor that 
is crucial for maturation signaling30. G-
CSF therapy can cause cataract and this 
adverse event is dose related.31
CONCLUSION                                                                      
The use of rHuG-CSF remains first-line 
treatment for most CN patients, which 
greatly improved patient’s quality of 
life.
All CN patients, regardless of their 
treatment or response, are at risk to 
develop MDS/ or leukemia at an ac-
tual evidence of 11.5% and accumula-
tive incidence of 21% after 10 years. 
Careful monitoring for cytogenetic 
abnormalities and G-CSF-R mutation 
is necessary to initiate. Hematopoietic 
Stem Cell Transplant (HSCT) should 
be restricted to G-CSF non-respond and 
leukemic transformation.
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